Mr. Southwell has served as a member of our Board since 2005. From October 2018 to March 2023, he served as the Chief Executive Officer, and a member of the board of directors, of TScan Therapeutics, Inc., a Nasdaq-listed biotechnology company. Previously Mr. Southwell served as President and Chief Executive Officer of Inotek Pharmaceuticals, Inc., a formerly publicly listed biotechnology company from 2014 until its merger with Rocket Pharmaceuticals Inc., a Nasdaq-listed biotechnology company, in 2018. From March 2010 to September 2012, Mr. Southwell served as the Executive Vice President and Chief Financial Officer, and from 2008 to 2010 served as a member of the board of directors, of Human Genome Sciences, Inc., a formerly publicly listed biopharmaceutical company. Prior to joining Human Genome Sciences, he served as Executive Vice President and Chief Financial Officer of Sepracor, Inc., a research-based pharmaceutical company, from June 1994 to March 2008, and as Sepracor’s Senior Vice President and Chief Financial Officer, from 1994 to 1995. From August 1988 until 1994, Mr. Southwell was associated with Lehman Brothers Inc., a securities firm, in various positions within the investment banking division. Mr. Southwell currently serves on the board of directors of Rocket Pharmaceuticals. From 2018 to 2019, Mr. Southwell served on the board of directors of Spero Therapeutics, Inc., a Nasdaq-listed biotechnology company. During 2016, Mr. Southwell served on the board of directors of inVentiv Health, Inc., a contract research organization prior to its recapitalization in late 2016. From 2007 to 2016, Mr. Southwell served on the board of directors of THL Credit, Inc., a Nasdaq-listed business development company under the Investment Company Act of 1940. Mr. Southwell received a B.A. from Rice University and an M.B.A. from the Tuck School of Business at Dartmouth College.
What is David P. Southwell's net worth?
The estimated net worth of David P. Southwell is at least $4.95 million as of April 12th, 2024. Mr. Southwell owns 95,160 shares of PTC Therapeutics stock worth more than $4,954,981 as of December 3rd. This net worth approximation does not reflect any other assets that Mr. Southwell may own. Learn More about David P. Southwell's net worth.
How do I contact David P. Southwell?
Has David P. Southwell been buying or selling shares of PTC Therapeutics?
David P. Southwell has not been actively trading shares of PTC Therapeutics over the course of the past ninety days. Most recently, David P. Southwell sold 11,429 shares of the business's stock in a transaction on Monday, April 17th. The shares were sold at an average price of $51.03, for a transaction totalling $583,221.87. Following the completion of the sale, the director now directly owns 10,500 shares of the company's stock, valued at $535,815. Learn More on David P. Southwell's trading history.
Who are PTC Therapeutics' active insiders?
PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?
During the last twelve months, PTC Therapeutics insiders bought shares 1 times. They purchased a total of 7,700 shares worth more than $198,737.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 56,906 shares worth more than $1,787,917.16. The most recent insider tranaction occured on July, 16th when CFO Pierre Gravier sold 2,269 shares worth more than $77,191.38. Insiders at PTC Therapeutics own 5.5% of the company.
Learn More about insider trades at PTC Therapeutics. Information on this page was last updated on 7/16/2024.
